
Scilex Holding Company
- Jurisdiction
United States - ISIN
US80880W1062 (SCLX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Read full profile
Stock price
Fundamentals
- Net revenue
€37.95M - Gross margin
70.4% - EBIT
-€82.97M - EBIT margin
-218.6% - Net income
-€105.52M - Net margin
-278.0%
Statement period: - (published )
Dividends
No dividend payouts
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |